Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 9/20 | 0.64 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.64 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.64 |
| ▸ | HTR3B | O95264 | 4/20 | 0.64 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.64 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | THPO | P40225 | 1/20 | 0.64 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1500715 | 0.89 | HRH4 (0.68) | HTR3AHRH4HTR3EHTR3BHTR3D | |
| SCHEMBL29772252 | 0.85 | HTR3A (0.47) | HTR3AHRH4HTR3EHTR3BHTR3D | |
| SCHEMBL23273855 | 0.85 | HTR3A (0.47) | HTR3AHRH4HTR3EHTR3BHTR3D | |
| SCHEMBL21588490 | 0.81 | SMN1; SMN2 (0.49) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL2621746 | 0.80 | HRH4 (0.66) | HTR3AHRH4HTR3EHTR3BHTR3D | |
| SCHEMBL29780593 | 0.80 | HRH4 (0.66) | HTR3AHRH4HTR3EHTR3BHTR3D | |
| SCHEMBL606721 | 0.78 | HRH3 (1.00) | HTR3AHRH4HTR3EHTR3BHTR3D | |
| SCHEMBL20651331 | 0.74 | HRH4 (0.70) | HTR3AHRH4HTR3EHTR3BHTR3D | |
| SCHEMBL1500092 | 0.73 | ALDH1A1 (0.50) | HTR3AHRH4HTR3EHTR3BHTR3D | |
| SCHEMBL25138077 | 0.73 | HTR3A (0.70) | HTR3AHRH4HTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171432-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| EP-4469447-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| WO-2023146989-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146989-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-4167982-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-16 | — | — | US | disclosed |
| WO-2021262596-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021262596-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | HTR3A 3685/4885HRH4 4614/4885HTR3E 3799/4885 |
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | HTR3A 3685/4885HRH4 4614/4885HTR3E 3799/4885 |
| US-20250171432-A1 | COMPOUNDS AND METHODS OF USE | ABCG2, F12, CYP2C9 | HTR3A 1114/4885HRH4 145/4885HTR3E 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.